Highlights Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-12 EST			5-day change	1st Jan Change
95.35 ^USD	+3.36%		+6.36%	+147.02%

12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI
11-06	Protagonist Therapeutics Q3 net loss widens to $39.3 mln	RE

Highlights

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	12-06	CI
Protagonist Therapeutics Q3 net loss widens to $39.3 mln	11-06	RE
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q3 Revenue $4.7M, vs. FactSet Est of $3.8M	11-06	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	11-06	CI
Protagonist Therapeutics Insider Sold Shares Worth $979,480, According to a Recent SEC Filing	10-14	MT
Deals of the day-Mergers and acquisitions	10-10	RE
Sector Update: Health Care Stocks Decline Friday Afternoon	10-10	MT
Johnson & Johnson Reportedly in Talks to Buy Protagonist Therapeutics	10-10	CI
Johnson & Johnson in Talks to Acquire Protagonist Therapeutics	10-10	MT
Protagonist Therapeutics Leaps on Report of Possible J&J Deal	10-10	DJ
Johnson & Johnson in Talks to Acquire Protagonist Therapeutics	10-10	MT
Johnson & Johnson in Talks to Acquire Protagonist Therapeutics, WSJ Reports	10-10	MT
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says	10-10	RE
Johnson & Johnson in talks to buy Protagonist Therapeutics - WSJ	10-10	RE
Protagonist Therapeutics Says Rusfertide Gets US FDA Breakthrough Therapy Designation for Blood Condition Treatment	08-25	MT
Protagonist Therapeutics Q2 net loss beats expectations	08-06	RE
Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	08-06	CI
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	06-02	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-06	CI
Sector Update: Health Care Stocks Decline Late Afternoon	03-10	MT
Protagonist Therapeutics, Inc. Announces New Icotrokinra (Jnj-2113) Data from the Comprehensive Phase 3 Clinical Program and the Planned Initiation of the First-Ever Head-To-Head Study in Plaque Psoriasis	03-10	CI
Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera	03-03	CI
Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise	02-21	MT
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M	02-21	MT
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98	02-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Highlights

Filters